Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil

Osaki,Akihiko; Mitsuyama,Shoshu; Kurebayashi,Jun-Ichi; Sonoo,Hiroshi; Nishimura,Reiki; Koga,Toshihiro; Murakami,Shigeru; Ohno,Shinji

doi:10.3892/ol_00000008

Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil

Authors:
- Akihiko Osaki
- Shoshu Mitsuyama
- Jun-Ichi Kurebayashi
- Hiroshi Sonoo
- Reiki Nishimura
- Toshihiro Koga
- Shigeru Murakami
- Shinji Ohno
View Affiliations

Affiliations: Department of Breast Oncology, Saitama Medical University, Saitama 350-1298, Japan. aosaki@saitama-med.ac.jp
Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000008
Pages: 45-49

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The study present the results of the dose-setting study of concomitant weekly administration of paclitaxel and tegafur·uracil (UFT) for metastatic breast cancer. Eligible patients who entered the study underwent two or more courses of weekly paclitaxel + UFT therapy as the protocol therapy. The initial dose (level 1) was paclitaxel, 80 mg/m2 and UFT, 400 mg/day. At level 2, paclitaxel remained the same, but UFT was increased to 600 mg/day. At level 3, only paclitaxel was increased to 90 mg/m2. Twelve patients were enrolled in this study between September 2000 and September 2002. Three patients were assigned to level 1. Grade 3 liver dysfunction (increased aspartate aminotransferase and alanine aminotransferase) was noted in one patient and grade 4 neutropenia was noted in one patient, showing that dose-limiting toxicity was detected in 2/3 patients. In accordance with the protocol, UFT was fixed at 400 mg/day and paclitaxel was decreased to 60 mg/m2 at level −1, and then increased to 70 mg/m2 at level 0. The overall effective rate after completion of two courses was 33% (3/9) including one case of complete response and two cases of partial responses. The remaining patients presented with stable diseases and no patient had progressive disease. In this study, weekly paclitaxel with concomitant UFT was administered. The recommended doses of paclitaxel and UFT were determined to be 70 mg/m2 and 400 mg/day, respectively. As the toxicity profile shows, the highest toxicity level of this regimen was neutropenia and liver dysfunction, and dose-limiting toxicity was neutropenia.

View Figures

View References

1	A’Hern RP, Smith IE and Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer. 67:801–805. 1993.PubMed/NCBI
2	Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A and Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 16:3439–3460. 1998.PubMed/NCBI
3	Paterson AH, Szafran O, Cornish F, Lees AW and Hanson J: Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat. 1:357–363. 1981. View Article : Google Scholar : PubMed/NCBI
4	Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N and Fountzilas G: Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol. 23:147–160. 2006. View Article : Google Scholar
5	Polyzos A, Tsavaris N, Kosmas C, Gogas H, Toufexi H, Kosmidis C, Markopoulos C, Giannopoulos A, Papadopoulos O, Stamatiadis D and Kouraklis G: Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study. J Chemother. 15:607–612. 2003. View Article : Google Scholar : PubMed/NCBI
6	Seo JH, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Kim AR, Lee JB and Koo BH: Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol. 59:269–274. 2007.PubMed/NCBI
7	Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 83:1797–1805. 1991. View Article : Google Scholar : PubMed/NCBI
8	Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol. 13:1152–1159. 1995.PubMed/NCBI
9	Ito Y, Horikoshi N, Watanabe T, Sasaki Y, Tominaga T, Okawa T, Tabei T, Kuraishi Y, Tamura K, Abe R, Kitajima M, Yamaguchi S, Kobayashi T, Koyama H, Orita K, Takashima S, Nomura Y and Ogawa M: Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group. Invest New Drugs. 16:183–190. 1998. View Article : Google Scholar : PubMed/NCBI
10	Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J and Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 16:3353–3361. 1998.PubMed/NCBI
11	Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 7:425–432. 1989.
12	Ota K, Taguchi T and Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 22:333–338. 1988.PubMed/NCBI
13	Tashiro H, Nomura Y and Ohsaki A: A double blind comparative study of tegafur (FT) and UFT (a combination of tegafur and uracil) in advanced breast cancer. Jpn J Clin Oncol. 24:212–217. 1994.PubMed/NCBI
14	Passardi A, Maltoni R, Milandri C, Cecconetto L, Massa I, Zoli W, Tesei A, Fabbri F, Nanni O and Amadori D: Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies. Oncology. 72:118–124. 2007. View Article : Google Scholar : PubMed/NCBI
15	Kim R, Osaki A and Toge T: Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer. Oncol Rep. 10:145–150. 2003.PubMed/NCBI
16	Kimura M, Koida T and Yanagita Y: Weekly administration of paclitaxel for advanced or metastatic breast cancer-short-course premedications for outpatients. Gan To Kagaku Ryoho. 27:1703–1708. 2000.PubMed/NCBI